JPWO2019191694A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019191694A5
JPWO2019191694A5 JP2020552294A JP2020552294A JPWO2019191694A5 JP WO2019191694 A5 JPWO2019191694 A5 JP WO2019191694A5 JP 2020552294 A JP2020552294 A JP 2020552294A JP 2020552294 A JP2020552294 A JP 2020552294A JP WO2019191694 A5 JPWO2019191694 A5 JP WO2019191694A5
Authority
JP
Japan
Prior art keywords
composition
acid
rdna sequence
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519763A (ja
JP2021519763A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025010 external-priority patent/WO2019191694A1/en
Publication of JP2021519763A publication Critical patent/JP2021519763A/ja
Publication of JP2021519763A5 publication Critical patent/JP2021519763A5/ja
Publication of JPWO2019191694A5 publication Critical patent/JPWO2019191694A5/ja
Pending legal-status Critical Current

Links

JP2020552294A 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法 Pending JP2021519763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650002P 2018-03-29 2018-03-29
US62/650,002 2018-03-29
PCT/US2019/025010 WO2019191694A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2021519763A JP2021519763A (ja) 2021-08-12
JP2021519763A5 JP2021519763A5 (https=) 2022-04-06
JPWO2019191694A5 true JPWO2019191694A5 (https=) 2022-04-06

Family

ID=66429534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552294A Pending JP2021519763A (ja) 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法

Country Status (10)

Country Link
US (1) US20210121505A1 (https=)
EP (1) EP3773643A1 (https=)
JP (1) JP2021519763A (https=)
KR (1) KR20200138333A (https=)
CN (1) CN112118852A (https=)
AU (1) AU2019245430A1 (https=)
BR (1) BR112020019979A2 (https=)
CA (1) CA3095402A1 (https=)
MX (1) MX2020010177A (https=)
WO (1) WO2019191694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
KR102341323B1 (ko) * 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
WO2025244478A1 (ko) * 2024-05-24 2025-11-27 서울대학교병원 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP5921894B2 (ja) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 腸内酪酸産生菌増加剤
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
JP6624903B2 (ja) * 2015-11-25 2019-12-25 学校法人東京理科大学 消毒剤及び消毒方法
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CN110545828A (zh) * 2016-04-19 2019-12-06 基因组研究有限公司 细菌疗法
JP7168558B2 (ja) * 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Clostridium difficile感染症の処置
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2021519763A5 (https=)
Jena et al. Probiotics VSL# 3 are effective in reversing non-alcoholic steatohepatitis in a mouse model
Poritz et al. Remicade® does not abolish the need for surgery in fistulizing Crohn’s disease
US6426340B1 (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-FUDCA)
Trauner et al. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
Hui et al. Capsaicin improves glucose homeostasis by enhancing glucagon‐like peptide‐1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice
JP2022166039A (ja) 肝内胆汁うっ滞および関連肝疾患の治療
RU2020110462A (ru) Композиции и способы для лечения холестатического заболевания
JPWO2019191694A5 (https=)
EP0293751B1 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
Wang et al. Alterations of gut microbiota and serum bile acids are associated with parenteral nutrition-associated liver disease
US9446058B2 (en) Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
Liu et al. The farnesoid X receptor agonist tropifexor prevents liver damage in parenteral nutrition‐fed neonatal piglets
Shen et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis
Safarovich Influence of intestinal microflora on the development of gallstone disease (literature review)
US6348495B1 (en) Method for treating celiac disease
HK1243646A1 (zh) 用於调节骨密度的方法
福島恒男 et al. DISORDERS OF BILE ACID AND OXALTE METABOLISM IN CROHN'S DISEASE
CN109700833B (zh) 一种用于治疗便秘的药物组合物及其制备方法和应用
Derbak et al. Correction of Intestinal Dysbiosis in Patients with Chronic Hepatitis C against the Background of non-alcoholic Fatty Liver Disease
Owen et al. Faecal steroid loss in healthy subjects during short-term treatment with ursodeoxycholic acid
YAO et al. Regulatory effect of compound Agrimonia pilosula enteritis capsule on bile acid metabolism in improving ulcerative colitis with dampness-heat syndrome
Takikawa et al. Absorption of unconjugated bile acids and tauroursodeoxycholate in the rat intestine
IR April 1995 Immunology, Microbiology, and Inflammatory Disorders A909
Samson et al. Increased serine dependent proteinases in ulcerative colitis: mucolysis and inhibition by diosmectite